Sign In
Last checked at 
25 Mar 2026 08:00
Faron Pharmaceuticals Ltd | Company announcement | March 25, 2026 at 10:00:00 EET
TURKU, FINLAND â€" Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, announces today that Sirpa Jalkanen, Scientific founder of the Company and spouse of Board member Markku Jalkanen, subscribed 100,008 ordinary shares in Faron at price of €0.5 per share on 24 March 2026, pursuant to the Rights Issue announced by the Company on 10 March 2026.
Further details are set out in the Notification of Dealing Form below.
For more information, please contact:
| IR Partners, Finland(Media)Kare Laukkanen | +358 50 553 9535 / +44 7 469 766 223kare.laukkanen@irpartners.fi |
| FINN Partners, US(Media) Alyssa Paldo | +1 847 791-8085 alyssa.paldo@finnpartners.com |
| Cairn Financial Advisers LLP(Nominated Adviser and Broker)Sandy Jamieson, Jo Turner | +44 (0) 207 213 0880 |
| Sisu Partners Oy(Certified Adviser on Nasdaq First North)Juha KarttunenJukka J¤rvel¤ | +358 (0)40 555 4727+358 (0)50 553 8990 |
About bexmarilimabBexmarilimab is Faron’s wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.
About Faron Pharmaceuticals LtdFaron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company’s lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com
| Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 | |||||
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||||
| a. | Name | Sirpa Jalkanen | |||
| 2 | Reason for notification | ||||
| a. | Position/Status | PCA | |||
| b. | Initial notification/Amendment | Initial Notification | |||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
| a. | Name | Faron Pharmaceuticals Ltd. | |||
| b. | LEI | 7437009H31TO1DC0EB42 | |||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
| a. | Description of the financial instrument, type of instrumentIdentification Code | Subscription for new ordinary shares, pursuant to a rights issueISIN: FI4000153309 | |||
| b. | Nature of the transaction | Subscription | |||
| Price(s) per share (p) | Volume(s) | ||||
| EUR 0.5 | 100,008 | ||||
| d. | Aggregated informationVolumePrice | Transaction details (a)(1): Volume 100,008 Unit price: 0.5 EUR | |||
| e. | Date of the transaction | 24.3.2026 | |||
| f. | Place of the transaction | Nasdaq First North Growth Market | |||
Follow the stocks
